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ABSTRACT
Background: Significant functional impairment of the hands is nearly universal in systemic sclerosis (SSc, sclero-
derma). Hand exercises may improve hand function, but developing, testing and disseminating rehabilitation in-
terventions in SSc is challenging. The Scleroderma Patient-centered Intervention Network (SPIN) was established 
to address this issue and has developed an online hand exercise program to improve hand function for SSc pa-
tients (SPIN-HAND). The aim of the proposed feasibility trial is to evaluate the feasibility of conducting a full-scale 
randomized controlled trial (RCT) of the SPIN-HAND intervention.
Design and methods: The SPIN-HAND feasibility trial will be conducted via the SPIN Cohort. The SPIN Cohort 
was developed as a framework for embedded pragmatic trials using the cohort multiple RCT design. In total, 40 
English-speaking SPIN Cohort participants with at least mild hand function limitations (Cochin Hand Function 
Scale ≥3) and an indicated interest in using an online hand-exercise intervention will be randomized with a 1:1 
ratio to be offered to use the SPIN-HAND program or usual care for 3 months. The primary aim is to evaluate the 
trial implementation processes, required resources and management, scientific aspects, and participant accept-
ability and usage of the SPIN-HAND program.
Discussion: The SPIN-HAND exercise program is a self-help tool that may improve hand function in patients with 
SSc. The SPIN-HAND feasibility trial will ensure that trial methodology is robust, feasible, and consistent with trial 
participant expectations. The results will guide adjustments that need to be implemented before undertaking a 
full-scale RCT of the SPIN-HAND program. 
Trial registration: ClinicalTrials.gov Identifier: NCT03092024. 
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Introduction
Systemic sclerosis (SSc, or scleroderma) is a rare autoim-
mune disease that affects the skin and internal organs includ-
ing lungs, gastrointestinal tract and cardiovascular system 
(1, 2). Patient-reported problems include limitations in physical 
mobility and hand function, pain, fatigue, sleep disturbance, 
depression, sexual dysfunction, and appearance changes 
(3-6). Despite significant advances in symptom management, 
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there is still no disease-modifying agent; thus, a primary goal 
of care is to reduce disability and improve health-related qual-
ity of life (HRQL) (7).
Psychosocial, educational and rehabilitation interventions 
can improve disease management and function, and these in-
terventions are important components of patient-centered care 
in more common diseases. There are barriers to developing, 
testing and disseminating these interventions in rare diseases 
(8), and many rare disease patients, including people  living with 
SSc, face unique challenges that are not addressed by interven-
tions developed for more common conditions (9-12).
The Scleroderma Patient-centered Intervention Network 
(SPIN) was established to address this issue (8). SPIN is a 
collaboration of clinicians, patients and investigators from 
Canada, the USA, Europe and Latin America (www.spinsclero.
com). Over 1900 SSc patients from over 40 centers have been 
enrolled in SPIN’s web-based cohort. SPIN investigators are 
developing a series of online interventions to be tested with 
SPIN Cohort participants in pragmatic randomized controlled 
trials (RCTs).
The first SPIN intervention to be tested is an online pro-
gram of hand exercises designed to improve hand function 
(SPIN-HAND). Contractures and deformities of the hand, con-
sisting of decreased flexion and limited extension as well as 
reduced thumb abduction, are present in approximately 90% 
of SSc patients (3, 13). Impaired hand function is a major con-
tributor to overall disability and reduced HRQL (13, 14), and 
SSc patients rank impaired hand function at the top of their 
list of problems that impact their daily lives (3, 13).
Three RCTs have evaluated physical or occupational 
therapy interventions to improve hand function in SSc, but 
all were limited by small samples (n<20 per arm) and signifi-
cant methodological shortcomings (15). Additionally, Schouf-
foer et al (16) reported that a 12-week multidisciplinary day 
treatment program, which included hand exercises, improved 
grip strength and reduced disability compared to usual care 
24 weeks post-randomization (n = 53). Recently, another RCT 
tested a one-month general SSc home-based exercise thera-
py program, which included hand exercises (n = 218) (17). The 
program improved hand function significantly at 6-months 
follow-up, but gains were no longer statistically significant 
at 12-months post-randomization. Possible reasons why the 
impact of the intervention on hand function was not greater 
and longer lasting include that it was a general exercise pro-
gram that did not focus specifically on hand function and that 
the one-month program did not provide resources to support 
ongoing patient adherence. In post-trial interviews, patients 
encouraged the development of an internet-based tool to in-
crease ongoing adherence and motivation (manuscript under 
review).
Prior to a full-scale RCT, a feasibility trial of SPIN-HAND 
will be conducted to ensure the feasibility of the planned trial 
methodology and that the online intervention is user-friendly 
and acceptable to trial participants (18-21). Feasibility study 
outcomes will inform and guide adjustments to the online in-
tervention and the trial protocol that might need to be imple-
mented before undertaking the full-scale SPIN-HAND RCT to 
assess effectiveness.
The aim of the proposed feasibility trial is to evaluate the 
feasibility of conducting a full-scale RCT of the SPIN-HAND 
 intervention by obtaining data related to the study’s process, 
required resources and management, scientific aspects, and 
participant acceptability. The SPIN-HAND feasibility study is 
not meant for hypothesis testing or effect size estimation, as 
the sample size is not appropriate to do so.
Methods
Design and setting
The SPIN-HAND feasibility trial will be conducted via the 
SPIN Cohort. The SPIN Cohort was developed as a framework 
for embedded pragmatic trials using the cohort multiple RCT 
(cmRCT) design. In the cmRCT design (22), participants enroll 
in an observational cohort with regular outcome measure-
ment. Participants consent to allow their data to be used for 
observational studies. They consent to allow their data to be 
used to assess intervention trial eligibility and, if eligible, to 
be randomized to the intervention or control arm of the trial. 
They also consent that if they are eligible and randomized 
to the intervention arm, they will be contacted and offered 
access to the intervention; finally, they consent that if eligi-
ble and randomized to usual care, they will not be notified 
that they are involved in the trial usual care group, but their 
regularly collected cohort data will be used to evaluate trial 
outcomes. Trial eligibility will be assessed during regular SPIN 
Cohort assessments, which occur every 3 months, and trial 
outcomes will be obtained at the subsequent SPIN Cohort as-
sessment 3 months later.
Participants
To be eligible for the SPIN Cohort, patients must be classi-
fied as having SSc based on 2013 (23) ACR/EULAR criteria con-
firmed by a SPIN physician, be aged ≥18 years, be able to give 
informed consent, be fluent in English, French or  Spanish, and 
be able to respond to questionnaires via the internet. Since 
this is a pragmatic trial that intends to determine if providing 
the SPIN-HAND Program, in addition to usual care, improves 
hand outcomes, patients will not be excluded if they are en-
gaged in hand exercises as part of their usual care. The SPIN 
Cohort is a convenience sample. Eligible SPIN Cohort patients 
are recruited at SPIN sites (www.spinsclero.com/en/sites) 
during regular medical visits, and written informed consent is 
obtained. A medical data form is submitted online by the site 
to enroll participants. Cohort participants complete outcome 
measures via the internet upon enrollment and subsequently 
every 3 months (8).
For the SPIN-HAND feasibility trial, 40 English-speaking 
SPIN Cohort participants will be randomized with a 1:1 ra-
tio to be offered to use the SPIN-HAND program or usual 
care, defined as the standard care that they receive from 
their regular healthcare providers. Cohort participants will 
be eligible for the feasibility trial if they complete their SPIN 
 Cohort measures in English, have at least mild hand function 
limitations (Cochin Hand Function Scale (24)] [CHFS] ≥3), and 
have indicated high interest in using an online hand exercise 
intervention (≥7 on a 0-10 scale). Assessment of hand func-
tion limitations and interest will occur as part of participants’ 
regular SPIN Cohort assessments.
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Procedure: randomization, allocation concealment,  
consent and blinding
Randomization to be offered versus not offered, the 
SPIN-HAND intervention will occur at the time of Cohort par-
ticipants’ regular SPIN Cohort assessments. Eligible Cohort 
participants, based on questionnaire responses, will be ran-
domized automatically as they complete their regular SPIN 
Cohort assessments using a feature in the SPIN Cohort plat-
form, which provides immediate centralized randomization 
and, thus, complete allocation sequence concealment. Partic-
ipants randomized to be offered the intervention will receive 
an automated email invitation including a link to the SPIN-
HAND program site and the SPIN-HAND feasibility study con-
sent form. At initial login, they will be prompted to provide 
written consent to participate in the SPIN-HAND feasibility 
study by verifying agreement with consent elements and pro-
viding their email address as the signature. Participants who 
consent will be automatically re-directed to the introduction 
page of the SPIN-HAND program. Patients who log out before 
agreeing to the terms of the consent form will return to the 
consent page upon subsequent logins. SPIN personnel will 
also contact participants by phone, usually within 48 hours of 
sending the invitation email, to describe the study, review the 
consent form, and answer questions. Participants who accept 
the offer to use the SPIN-HAND intervention can use the web 
link to enter the secure intervention site. Email and phone 
technical support will be available to help participants with 
the consent process and to access and use the intervention 
site. See Figure 1 for SPIN Cohort participants flow through 
the SPIN-HAND feasibility trial.
In pragmatic trials, participants are typically not blinded to 
intervention status and possible biases are accepted as part of 
the response to being offered an intervention, as may occur 
in practice (25, 26). Disappointment bias, however, can occur 
in conventional trial designs when a participant enrolls in a 
trial to receive an intervention, but is allocated to usual care 
(22, 25). For this reason, in the cmRCT design (22), participants 
who are not offered an intervention are not notified that they 
have not been offered the intervention. This replicates actual 
practice, where patients are not typically advised about treat-
ments that are not options, and reduces risk of disappoint-
ment bias (22, 26, 27). All participants in the SPIN Cohort are 
aware that SPIN will conduct intervention trials and are rou-
tinely asked about potential interest in nine possible interven-
tions, but are not informed that any particular intervention 
may be available unless they are offered to try the interven-
tion. Thus, participants who are offered the intervention are 
not blind to their status, whereas participants assigned to usu-
al care are blind to their participation in the trial and trial arm.
Intervention
Home-based exercise rehabilitation programs have been 
shown to improve hand function in SSc (17) and rheumatoid 
arthritis (28, 29). SPIN’s hand exercise program is based on 
these programs and integrates key components of success-
ful disease self-management programs, including goal-setting 
and feedback, social modeling, and mastery experiences 
(30-33). The SPIN-HAND exercise program was designed by 
SPIN experts in physical medicine, rehabilitation, physical and 
occupational therapy, and behavioral therapies, together with 
patient representatives. The core of the program consists of 
four modules that address specific aspects of hand function, 
including (1) Thumb Flexibility and Strength (3 exercises); (2) 
Finger Bending (3 exercises); (3) Finger Extension (3 exercises); 
and (4) Wrist Flexibility and Strength (2 exercises). Participants 
can select the modules in the order that they prefer, based on 
a description of the type of function that the module is tar-
geting to maintain or improve. The program includes sections 
on developing a personalized program, goal-setting strategies 
and examples, progress tracking, sharing goals and progress 
with friends and family, and patient stories of experiences 
with hand disability and hand exercises. The program utilizes 
an engaging and easy-to-navigate web interface. Instructional 
videos with SSc patients demonstrate and explain how to per-
form each exercise properly, and additional pictures illustrate 
common mistakes. Separate versions of each exercise are 
available for participants with mild-to-moderate and more 
severe hand involvement. In the SPIN-HAND program, partici-
pants can identify their level by reviewing photos of hands of 
patients with mild-to-moderate versus more severe involve-
ment. Some exercise videos include pictures to illustrate al-
ternate versions on how to perform the exercise when there 
is very severe hand involvement. Participants are provided 
guidance on selecting intervention intensity levels. For the 
first 4 weeks of the program, it is suggested that they focus 
on exercises in one module per week and are encouraged 
Fig. 1 - Scleroderma Patient-centered Intervention Network (SPIN) 
Cohort and Feasibility Trial Flow (numbers of SPIN Cohort patients 
as of July 24, 2017).
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to do the exercises 3-5 times per week. Time per day gradu-
ates from 3-4 minutes in week 1, to 5-15 minutes in week 4. 
 Starting with week 5, participants are asked to select from a 
menu of program options to fit their needs and schedule. Op-
tions range from 5-10 minutes per day to 30-35 minutes per 
day. Participants offered the program will be able to access it 
for the entire 3-month trial period.
Outcomes and measurement
The primary aim of the SPIN-HAND feasibility study is 
to collect data related to the study’s process to assess the 
feasibility of the steps that need to take place as part of 
the main study; required resources and management (e.g., 
personnel and data management issues); scientific aspects 
(e.g., outcome assessments), and participant acceptability 
(e.g., ease of use). Data will be used to determine whether 
it is feasible to carry on the main study or whether changes 
need to be made before undertaking a full-scale RCT. The 
feasibility trial outcomes related to the process and resourc-
es will be assessed throughout the duration of the feasibil-
ity trial, and participant feedback will be obtained 3 months 
post-randomization.
Outcomes and measures
Process and resources
Information to be collected includes: (1) the proportion 
of SPIN Cohort participants who meet eligibility criteria; (2) 
proper functioning of automated eligibility and randomiza-
tion procedures; (3) the proportion of eligible participants 
randomized to be offered the SPIN-HAND intervention who 
accept the offer and consent to participate; (4) complete-
ness of online data collection for each trial arm at 3-month 
follow-up; (5) completeness of the intervention usage log 
data; (6) ability to successfully link data coming from the 
SPIN Cohort and SPIN-HAND platforms; (7) rate of comple-
tion of trial outcome variables; (8) personnel requirements 
to call enrolled participants and help them to consent and 
use the SPIN-HAND program; (9) other challenges for study 
personnel; and (10) technological performance of the online 
SPIN-HAND program.
Participant use and acceptability of SPIN-HAND  
intervention, implementation of trial procedures
Usage of the SPIN-HAND program modules among partici-
pants in the intervention arm will be examined via intervention 
usage data. These data will provide detailed information on 
number of logins, number of modules accessed, goals set, as 
well as time spent on each webpage. Additionally, at 3-months’ 
post-randomization, qualitative interviews will be conducted 
with participants in the intervention arm to assess user accept-
ability and satisfaction. The semi-structured interview will be 
guided by items of the Patient Education Materials Assessment 
Tool for Audiovisual Materials (34) and will address topics re-
lated to usability, understandability, organization, and clarity. 
Participant feedback from these interviews will inform any 
changes necessary to improve the SPIN-HAND program prior 
to conducting a full-scale RCT (see SPIN-HAND Intervention 
 Patient Interviews, available online as Supplementary Material 
at www.sclerodermajournal.com).
Trial personnel time requirements will be logged, and trial 
personnel will be interviewed to understand any implemen-
tation challenges.
Trial measures
The objectives of the full-scale SPIN-HAND RCT will be 
to evaluate the effect of being offered access to SPIN’s on-
line hand exercise program, compared to usual care alone, 
on hand function (primary), functional health outcomes, and 
HRQL. In both the present feasibility study and the full-scale 
RCT, outcome measures are routinely assessed as part of the 
SPIN Cohort assessments every 3 months. Thus, no additional 
assessments will be added for the trial that are not already 
done as part of the SPIN Cohort.
The 18-item CHFS (24) was developed to measure hand 
function limitations among patients with rheumatic diseases. 
The CHFS assesses ability to perform hand-related activi-
ties (e.g., kitchen, dressing oneself, hygiene, writing/typing). 
Items are scored on a 0-5 Likert scale (0 = without difficulty; 
5 = impossible). Higher scores indicate less functionality. The 
total score is obtained by adding the scores of all items (range 
0-90). The CHFS has good convergent validity with general 
functional disability measures and good sensitivity to change 
(14, 24, 35, 36). It has been validated in SSc (36).
Patient-reported health status will be measured using the 
29-item Patient Reported Outcomes Measurement Informa-
tion System (PROMIS-29) profile version 2.0. The PROMIS-29 
measures seven domains of health status with four items 
each (physical function, anxiety, depression, fatigue, sleep 
disturbance, social roles and activities, pain interference) plus 
a single item for pain intensity. Domain items are scored on 
a 5-point scale (range 1-5), with different response options 
for different domains, whereas the single pain intensity item 
is measured on an 11-point rating scale. Higher scores rep-
resent more of the domain being measured; that is, better 
physical function and ability to participate in social roles and 
activities, but higher levels of anxiety, depression, fatigue, 
sleep disturbance, pain interference, and pain intensity. To-
tal raw scores are obtained by summing item scores for each 
domain, which are converted into T-scores standardized from 
the general US population (mean = 50, SD = 10). PROMIS-29 
version 2.0 has been validated in SSc (37, 38).
HRQL will be assessed with the EQ-5D (39), a 5-item stan-
dardized questionnaire, measuring five dimensions (mobil-
ity, self-care, usual activities, pain/discomfort, and anxiety/
depression). The items are rated from 1 (no problems) to 3 
(extreme problems).
Sample size
Guidance on the appropriate sample size for feasibility tri-
als varies substantially in the published literature, with rules-
of-thumb varying from n = 12 to n = 30 or more per trial arm 
(40, 41). To ensure that we collect sufficient quantitative and 
qualitative outcome data to meet our feasibility objectives 
and guide the next study phase, we will include a total of 40 
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SPIN Cohort participants in this feasibility trial (approximately 
20 per trial arm).
Data collection, storage and sharing
Outcome measures are completed through the partici-
pants’ regular SPIN Cohort assessments. The SPIN Cohort uses 
a secure electronic data management platform designed and 
managed by the Information Management Services (IMS) of 
the Centre for Clinical Epidemiology, Jewish General  Hospital, 
Montreal. Separate from the SPIN Cohort portal, an encrypted 
database has been created for the SPIN-HAND program, which 
includes an identification number for intervention participants 
to link to SPIN Cohort data and their usage log information.
Data analysis
The primary data analysis will present a description of 
feasibility outcomes, including participants’ eligibility and 
recruitment and numbers and percentages of participants 
who respond to follow-up measures. Use of the internet in-
tervention will be described by presenting the frequency of 
logins and time spent on the SPIN-HAND program. Analysis 
of outcome measures will include the completeness of data 
and presence of floor or ceiling effects. Descriptive statistics 
will be used to provide means and standard deviations for 
the measures. Qualitative information on participants’ expe-
rience using the SPIN-HAND intervention will be used to in-
terpret acceptability related to content, webpage visuals, and 
navigation. Information related to required resources and 
management of the program during feasibility will inform any 
necessary changes to intervention or trial procedures.
Adverse events
The risk of adverse events occurring as a consequence of 
the SPIN-HAND program is very low. All hand exercises recom-
mended are explained in detail with an emphasis on choosing 
a level that is comfortable for the study participant. Nonethe-
less, adverse events will be assessed via interview and open-
ended questions. Any events reported will be discussed with 
clinical members of the team and referrals to local SPIN physi-
cians will be made as necessary. Any serious adverse events 
that occur will also be reported to the ethics committee.
Ethics and trial registration
Ethics approval for the SPIN-HAND feasibility trial has 
been obtained from the Research Ethics Committee of the 
Jewish General Hospital, Montreal, Canada. The SPIN-HAND 
feasibility study was registered prior to participant enroll-
ment (NCT03092024) and will be reported in accordance 
with standards articulated in the Consolidated Standards of 
Reporting Trials (CONSORT) extensions for randomized pilot 
and feasibility trials (21).
Discussion
The SPIN-HAND exercise program may improve hand func-
tion in SSc patients. This feasibility study will ensure that trial 
methodology is robust, feasible, and consistent with partici-
pant expectations (18-21). Results will guide any changes that 
need to be implemented before conducting a full-scale RCT to 
test the effectiveness of the SPIN-HAND intervention. Based 
on current SPIN Cohort data, we anticipate that 45%-50% of 
Cohort patients will be eligible for the full-scale SPIN-HAND 
trial. Thus, we anticipate being able to easily meet recruit-
ment goals for that trial, and patients who are included in 
the intervention arm of the feasibility trial will not be eligible 
for the subsequent full-scale trial. If effective, it will be made 
available through patient organizations around the world to 
support people in their efforts to cope with living with SSc.
Acknowledgements
List of SPIN investigators
Murray Baron, McGill University, Montreal, Quebec, Canada; Susan J. 
Bartlett, Dan Furst, University of California, Los Angeles, California, 
USA; Karen Gottesman, Scleroderma Foundation, Los Angeles, Cali-
fornia, USA; McGill University, Montreal, Quebec, Canada; Frank van 
den Hoogen, Radboud University Medical Center and Sint Maartenskli-
niek, Nijmegen, The Netherlands; Vanessa Malcarne, San Diego State 
University, San Diego, California, USA; Maureen D. Mayes, University 
of Texas McGovern School of Medicine, Houston, Texas, USA; Warren 
R. Nielson, St. Joseph’s Health Care, London, Ontario, Canada; Robert 
Riggs, Scleroderma Foundation, Danvers, Massachusetts, USA; Fred-
rick Wigley, Johns Hopkins University School of Medicine, Baltimore, 
Maryland, USA; Shervin Assassi, University of Texas McGovern School 
of Medicine, Houston, Texas, USA; Angela Costa Maia, University of 
Minho, Braga, Portugal; Ghassan El-Baalbaki, Université du Québec à 
Montréal, Montreal, Quebec, Canada; Carolyn Ells, McGill University, 
Montreal, Quebec, Canada; Kim Fligelstone, Scleroderma Society, 
London, UK; Catherine Fortune, Scleroderma Society of Ontario, 
Hamilton, Ontario, Canada; Tracy Frech, University of Utah, Salt Lake 
City, Utah, USA; Dominique Godard, Association des Sclérodermiques 
de France, Sorel-Moussel, France; Daphna Harel, New York University, 
New York, New York, USA; Ann Impens, Midwestern University, Down-
ers Grove, Illinois, USA; Yeona Jang, McGill University,  Montreal, Que-
bec, Canada; Sindhu R. Johnson, Toronto Scleroderma Program, 
Mount Sinai Hospital, Toronto Western Hospital, and University of 
Toronto, Toronto, Ontario, Canada; Ann Tyrell Kennedy, Federation of 
European Scleroderma Associations, Dublin, Ireland; Annett Körner, 
McGill University, Montreal, Quebec, Canada;  Maggie Larche, 
 McMaster University, Hamilton, Ontario, Canada; Catarina Leite, Uni-
versity of Minho, Braga, Portugal; Carlo Marra, Memorial University, 
St. John’s, Newfoundland, Canada; Karen Nielsen, Scleroderma Soci-
ety of Ontario, Hamilton, Ontario, Canada; Janet Pope, University of 
Western Ontario, London, Ontario, Canada; Alexandra Portales, Aso-
ciación Española de Esclerodermia, Madrid, Spain; Tatiana Sofia Ro-
driguez Reyna, Instituto Nacional de Ciencias Médicas y Nutrición 
Salvador Zubirán, Mexico City, Mexico; Russell J. Steele, Jewish 
 General Hospital and McGill University, Montreal, Quebec, Canada; 
Maria E. Suarez-Almazor, University of Texas MD Anderson Cancer 
Center, Houston, Texas, USA; Durhane Wong-Rieger, Canadian Organi-
zation for Rare Disorders, Toronto, Ontario, Canada; Christian Agard, 
Centre Hospitalier Universitaire - Hôtel-Dieu de Nantes, Nantes, 
France; Alexandra Albert, Université Laval, Quebec, Quebec, Canada; 
Marc André, Centre Hospitalier Universitaire Gabriel- Montpied, Cler-
mont-Ferrand, France; Guylaine Arsenault, Université de Sherbrooke, 
Protocol for SPIN-HAND feasibility trial96 
Sherbrooke, Quebec, Canada; Nouria Benmostefa, Assistance Pub-
lique Hôpitaux de Paris - Hôpital Cochin, Paris, France; Ilham Benzida, 
Assistance Publique Hôpitaux de Paris - Hôpital St-Louis, Paris, France; 
Sabine Berthier, Centre Hospitalier Universitaire Dijon Bourgogne, Di-
jon, France; Lyne Bissonnette, Université de Sherbrooke , Sherbrooke, 
Quebec, Canada; Gilles Boire, Université de Sherbrooke, Sherbrooke, 
Quebec,  Canada; Alessandra Bruns, Université de Sherbrooke, Sher-
brooke, Quebec, Canada; Patricia Carreira, Servicio de Reumatologia 
del Hospital 12 de Octubre, Madrid, Spain; Marion Casadevall, Assis-
tance Publique Hôpitaux de Paris - Hôpital Cochin, Paris, France; Ben-
jamin Chaigne, Assistance Publique Hôpitaux de Paris - Hôpital 
Cochin, Paris, France; Lorinda Chung, Stanford University, Stanford, 
California, USA; Pascal Cohen, Assistance Publique Hôpitaux de Paris 
- Hôpital Cochin, Paris, France; Pierre  Dagenais, Université de Sher-
brooke, Sherbrooke, Quebec, Canada; Christopher Denton, Royal 
Free London Hospital, London, UK; Robyn Domsic, University of Pitts-
burgh, Pittsburgh, Pennsylvania, USA; James V. Dunne, St. Paul’s Hos-
pital and University of British Columbia, Vancouver, British Columbia, 
Canada; Regina Fare, Servicio de Reumatologia del Hospital 12 de 
Octubre,  Madrid, Spain; Dominique Farge-Bancel, Assistance Pub-
lique Hôpitaux de Paris - Hôpital St- Louis, Paris, France; Paul R. Fortin, 
CHU de Québec - Université Laval, Quebec, Quebec, Canada; Anna 
Gill, Royal Free London Hospital, London, UK; Jessica Gordon, Hospital 
for Special Surgery, New York City, New York, USA; Brigitte Granel-Rey, 
Aix Marseille Université, and Assistance Publique Hôpitaux de 
Marseille - Hôpital Nord, Marseille, France; Claire Grange, Centre Hos-
pitalier Lyon Sud, Lyon, France; Genevieve Gyger, Jewish General Hos-
pital and McGill University, Montreal, Quebec, Canada; Eric Hachulla, 
Centre Hospitalier Régional Universitaire de Lille -Hôpital Claude Hu-
riez, Lille, France;  Pierre-Yves Hatron, Centre Hospitalier Régional Uni-
versitaire de Lille - Hôpital Claude Huriez, Lille, France; Ariane L 
Herrick, University of Manchester, Salford Royal NHS Foundation 
Trust, Manchester, UK; Adrian Hij, Assistance Publique Hôpitaux de 
Paris - Hôpital St-Louis, Paris, France; Monique Hinchcliff, Northwest-
ern University, Chicago, Illinois, USA; Alena Ikic, Université Laval, Que-
bec, Quebec, Canada; Niall Jones, University of Alberta, Edmonton, 
Alberta, Canada; Artur Jose de B. Fernandes, Université de Sher-
brooke, Sherbrooke, Quebec, Canada; Suzanne Kafaja, University of 
California, Los Angeles, California, USA; Nader Khalidi, McMaster Uni-
versity, Hamilton, Ontario, Canada; Benjamin Korman, Northwestern 
University, Chicago, Illinois, Marc Lambert, Centre Hospitalier Région-
al Universitaire de Lille - Hôpital Claude Huriez, Lille, France; David 
Launay, Centre Hospitalier Régional Universitaire de Lille - Hôpital 
Claude Huriez, Lille, France; USA; Patrick Liang, Université de Sher-
brooke, Sherbrooke, Quebec, Canada; Jonathan London, Assistance 
Publique Hôpitaux de Paris - Hôpital Cochin, Paris, France; David Luna, 
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, 
Mexico City, Mexico; Joanne Manning, Salford Royal NHS Foundation 
Trust, Salford, UK; Maria Martin, Servicio de Reumatologia del Hospi-
tal 12 de Octubre, Madrid, Spain; Thierry Martin, Les Hôpitaux Uni-
versitaires de Strasbourg - Nouvel Hôpital Civil, Strasbourg, France; 
Ariel Masetto,  Université de Sherbrooke, Sherbrooke, Quebec, Cana-
da; François Maurier, Hôpitaux Privés de Metz - Hôpital Belle-Isle, 
Metz, France; Arsene Mekinian, Assistance Publique Hôpitaux de 
Paris - Hôpital  St-Antoine, Paris, France; Sheila Melchor, Servicio de 
Reumatologia del Hospital 12 de Octubre,  Madrid, Spain; Romain 
Paule, Assistance Publique Hôpitaux de Paris - Hôpital Cochin, Paris, 
France; Alexis Régent, Assistance Publique Hôpitaux de Paris - Hôpital 
Cochin, Paris, France; Sébastien Rivière, Assistance Publique Hôpitaux 
de Paris - Hôpital St-Antoine, Paris, France; David Robinson, University 
of Manitoba, Winnipeg, Manitoba, Canada; Esther Rodriguez, Servi-
cio de Reumatologia del  Hospital 12 de Octubre, Madrid, Spain; So-
phie Roux, Université de Sherbrooke, Sherbrooke, Quebec, Canada; 
Perrine Smets, Centre Hospitalier Universitaire Gabriel-Montpied, Cl-
ermont-Ferrand, France; Doug Smith, University of Ottawa, Ottawa, 
Ontario, Canada; Vincent Sobanski, Centre Hospitalier Régional Uni-
versitaire de Lille - Hôpital Claude Huriez, Lille, France; Robert Spiera, 
Hospital for Special Surgery, New York, New York, USA; Virginia Steen, 
Georgetown University, Washington, DC, USA; Evelyn Sutton, Dalhou-
sie University, Halifax, Nova Scotia, Canada; Benjamin Terrier, Assis-
tance Publique Hôpitaux de Paris - Hôpital Cochin, Paris, France; 
Carter Thorne, Southlake Regional Health Centre, Newmarket, On-
tario, Canada; John Varga, Northwestern University, Chicago, Illinois, 
USA; Pearce Wilcox, St. Paul’s Hospital and University of British Co-
lumbia, Vancouver, British Columbia, Canada; Julie Cumin, Jewish 
General Hospital, Montreal, Quebec, Canada; Rina S. Fox, San Diego 
State University and University of California, San Diego, San Diego, 
California, USA; Shadi Gholizadeh, San Diego State University and Uni-
versity of California, San Diego, San Diego, California, USA; Lisa R. Jew-
ett, Jewish General Hospital and McGill University, Montréal, Québec, 
Canada; Brooke Levis, Jewish General Hospital and McGill University, 
Montreal, Quebec, Canada; Sarah D. Mills, San Diego State University 
and University of California, San Diego, San Diego, California, USA; 
Mia R. Pepin, Jewish General Hospital, Montreal, Quebec, Canada; 
Kimberly Turner, Jewish General Hospital,  Montreal, Quebec, Canada.
The SPIN team is dedicating the SPIN-HAND program to the mem-
ory of Dr. Serge Poiraudeau, who led the SPIN-HAND project team, 
along with Dr. Luc Mouthon. Dr. Poiraudeau cared deeply for the qual-
ity of life and well-being of people living with scleroderma, and with-
out his leadership and dedication the SPIN-HAND program would not 
have been possible.
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